Doing the Right Thing Shouldn't Cost You.
As an independent primary care provider, you fight every day to keep your patients healthy and your practice doors open. Sending your most vulnerable patients to a massive hospital network for a 20-minute breathing test hurts them physically, and it bleeds your practice financially. It is time to rethink the referral.
The Right Thing for Them
Your elderly and COPD patients trust you. Forcing someone who is already struggling to breathe to drive 45 minutes down rural highways to an unfamiliar, crowded hospital lab is exhausting and intimidating. By bringing the test to the exam room they already know, you eliminate their anxiety, guarantee they get tested, and provide immediate, compassionate care.
The Right Thing for Your Business
Every time a patient leaves your office for a hospital PFT, you surrender the global diagnostic billing and risk losing the patient entirely to the specialist's network. DirectCare allows you to recapture that lost ancillary revenue—averaging $85 to $110 in net margin per test—putting that money back into your independent clinic where it belongs, so you can continue serving the community.
Morbidity & Mortality Impact
Why securing diagnostic data at the primary care level is a critical life-saving intervention.
Risks of Undiagnosed Obstruction
- Underdiagnosis: Up to 50% of patients with functionally significant COPD remain undiagnosed until severe exacerbations force emergency room visits.
- Mortality Spike: Patients hospitalized for severe COPD exacerbations face a 1-year mortality rate exceeding 20%.
- Blind Prescribing: Empiric prescribing of inhaled corticosteroids (ICS) without objective PFT confirmation increases pneumonia risks in non-asthmatic patients.
Impact of Proactive Monitoring
- Hospitalization Reduction: Annual spirometric monitoring linked to targeted LABA/LAMA therapy reduces acute exacerbation frequency by up to 25%.
- Lung Function Preservation: Early intervention limits the rapid decline of FEV1 characteristic of early-stage COPD.
- Medication Optimization: Objective reversibility testing ensures patients are receiving the correct therapeutic phenotype protocol.
The 12-Month Patient Trajectory
The Compliance Advantage: In-House vs. External Referral
No-Show Rate
No-Show Rate
Testing patients in their familiar medical home radically reduces diagnostic abandonment.
The Out-of-Town Referral
Patient prescribed empiric inhaler and referred to hospital lab 45 minutes away.
Patient abandons referral due to travel friction. Remains unmonitored on empiric therapy.
Patient suffers acute exacerbation. ER admission. Permanent loss of FEV1 capacity.
The DirectCare Model
Patient tested inside your clinic. Receives Inhaler Tech Education (CPT 94664).
Pulmonologist report confirms COPD. Targeted LAMA therapy initiated immediately.
Follow-up annual PFT completed locally. Disease progression stabilized. Zero hospital visits.
The Specialist Referral Trap
When primary care providers refer patients to outside pulmonary specialists solely to obtain diagnostic testing, they risk permanent network leakage.
- • 3 to 6 Month Delays: Waitlists for specialist intake appointments leave patients unmanaged and vulnerable.
- • Patient Network Leakage: The patient is frequently absorbed into the specialist's hospital network for ongoing chronic care.
- • Loss of Ancillary Revenue: The primary care practice permanently loses the global billing revenue for testing and follow-up Evaluation & Management (E/M) visits.
DirectCare brings the specialist's diagnostic tools *and* their interpretive overread directly to your EMR—allowing you to retain 100% management of your patient.
Testing Indications & Frequency
Indications for Testing
- • Chronic cough, sputum production, or progressive dyspnea.
- • History of heavy occupational, environmental, or tobacco smoke exposure.
- • Evaluation of chronic obstructive pulmonary disease (COPD) or asthma phenotypes.
- • Pre-operative pulmonary risk assessment for cardiothoracic or upper abdominal surgeries.
Testing Frequency
- • Baseline: Initial diagnostic evaluation when respiratory symptoms present.
- • Annual Monitoring: Essential for tracking disease progression or therapeutic response in stable patients.
- • Post-Exacerbation / High Risk: Multi-interval testing per year may be required for highly unstable patients or rapid decliners to establish new personal baselines.
Report Interpretation Workflow
Every completed PFT suite includes expert clinical interpretation structured to guide actionable patient management plans.
Preliminary RRT Read
Performed immediately on-site by our Supervisory Respiratory Therapist to guarantee technical quality, acceptable waveforms, and ATS criteria compliance.
Pulmonologist Final Read (24 – 48 Hours)
A comprehensive diagnostic report with specialist interpretation and targeted management recommendations is securely delivered to your EMR within 24 to 48 hours.
GOLD & GINA Diagnostic Standards
Referencing international consensus guidelines for obstructive lung disease staging and control.
GOLD Standards (COPD)
COPDDefines post-bronchodilator fixed ratio FEV1 / FVC < 0.70 as persistent airflow limitation. Severity grading utilizes predicted FEV1 percentages:
- • GOLD 1 (Mild): FEV1 ≥ 80% predicted
- • GOLD 2 (Moderate): 50% ≤ FEV1 < 80% predicted
- • GOLD 3 (Severe): 30% ≤ FEV1 < 50% predicted
- • GOLD 4 (Very Severe): FEV1 < 30% predicted
GINA Standards (Asthma)
AsthmaEmphasizes documented expiratory airflow limitation and significant bronchodilator reversibility:
- • Reversibility Positive: An increase in FEV1 or FVC by > 12% and > 200 mL from baseline 10–15 minutes post-bronchodilator administration.
- • Variability Assessment: Monitoring excessive daily peak expiratory flow (PEF) fluctuations to confirm bronchial hyperresponsiveness.